Alemtuzumab for giant cell hepatitis with autoimmune hemolytic anemia

Journal of Pediatric Gastroenterology and Nutrition

Volumn 45, Issue 5, 2007, Pages 596-599

  Rovelli, Attilio ^a   Corti, Paola ^a   Beretta, Chiara ^a   Bovo, Giorgio ^b   Conter, Valentino ^a   Mieli Vergani, Giorgina ^c  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b SAN GERARDO HOSPITAL   (Italy)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISONE; RITUXIMAB;

ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; CASE REPORT; CELIAC DISEASE; COOMBS TEST; DRUG WITHDRAWAL; GIANT CELL HEPATITIS; HEPATITIS; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INFANT; LIVER BIOPSY; MALE; PRIORITY JOURNAL; VIRUS REACTIVATION;

ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; AZATHIOPRINE; BIOPSY; CELIAC DISEASE; CHILD, PRESCHOOL; COOMBS' TEST; CYCLOSPORINE; DIAGNOSIS, DIFFERENTIAL; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HEPATITIS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LIVER; LIVER FUNCTION TESTS; MALE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISONE; RARE DISEASES; REMISSION INDUCTION;

EID: 37349102683     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e318033169f     Document Type: Article

References (20)

1. Gorelik M, Debski R, Frangoul H. Autoimmune hemolytic anemia with giant cell hepatitis: case report and review of the literature. J Pediatr Hematol Oncol 2004;26:837-9.
2. Melendez HV, Rela M, Baker AJ, et al. Liver transplant for giant cell hepatitis with autoimmune hemolytic anemia. Arch Dis Child 1997;77:249-51.
3. Akyldiz M, Karasu Z, Arikan C, et al. Successful liver transplantation for giant cell hepatitis and Coombs-positive hemolytic anemia: a case report. Pediatr Transplant 2005;9:630-3.
4. Hadzic N, Portmann B, Lewis I, et al. Coombs positive giant cell hepatitis - a new feature of Evans' syndrome. Arch Dis Child 1998;78:397-8.
5. Sykes M, Nikolic B. Treatment of severe autoimmune disease by stem-cell transplantation. Nature 2005;435:620-7.
6. Knechtle SJ. Present experience with Campath-1H in organ transplantation and its potential use in pediatric recipients. Pediatr Transplant 2004;8:106-12.
7. Hale G, Slavin S, Goldman JM, et al. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning. Bone Marrow Transplant 2002;30:797-804.
8. Coles A, Deans J, Compston A. Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench. Clin Neurol Neurosurg 2004;106:270-4.
9. Willis F, Marsh JC, Bevan DH, et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol 2001;114:891-8.
10. Gibbs SD, Westerman DA, McCormack C, et al. Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders. Br J Haematol 2005;130:87-91.
11. Cheung WW, Tse E, Leung AY, et al. Regular virologic surveillance showed very frequent cytomegalovirus reactivation in patients treated with alemtuzumab. Am J Hematol 2007;82:108-11.
12. Reiff A. A review of Campath in autoimmune disease: biologic therapy in the gray zone between immunosuppression and immunoablation. Hematology 2005;10:79-93.
13. Myers GD, Krance RA, Weiss H, et al. Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath). Bone Marrow Transplant 2005;36:1001-8.
14. Quartier P, Brethon B, Philippet P, et al. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001;358:1511-3.
15. Zecca M, Nobili B, Ramenghi U, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 2003;101:3857-61.
16. Gabrielli M, Candelli M, Franceschi F, et al. Primary autoimmune haemolytic anemia and celiac disease. Scand J Gastroenterol 2004;39:605-6.
17. Miller DG. Celiac disease with autoimmune haemolytic anaemia. Postgrad Med J 1984;60:629-30.
18. Bizzaro N, Villalta D, Tonutti E, et al. IgA and IgG tissue transglutaminase antibody prevalence and clinical significance in connective tissue diseases, inflammatory bowel disease, and primary biliary cirrhosis. Dig Dis Sci 2003;48:2360-5.
19. Villalta D, Crovatto M, Stella S, et al. False positive reactions for IgA and IgG anti-tissue transglutaminase antibodies in liver cirrhosis are common and method-dependent. Clin Chim Acta 2005;356:102-9.
20. Vivas S, de Morales JMR, Ramos F, Suarez-Vilela D. Alemtuzumab for refractory celiac disease in a patient at risk for enteropathy-associated T-cell lymphoma. N Engl J Med 2006;354:2514-5.